Lucid Diagnostics Inc.

NASDAQ (USD): Lucid Diagnostics Inc. (LUCD)

Last Price

1.01

Today's Change

-0.04 (3.80%)

Day's Change

0.993 - 1.04

Trading Volume

506,491

Profile
LUCD

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Lishan Aklog M.D. Dr. Lishan Aklog M.D.

Full Time Employees:  70 70

IPO Date:  2021-10-14 2021-10-14

CIK:  0001799011 0001799011

ISIN:  US54948X1090 US54948X1090

CUSIP:  54948X109 54948X109

Beta:  1.42 1.42

Last Dividend:  0.00 0.00

Dcf Diff:  1.97 1.97

Dcf:  -0.92 -0.92

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Address

One Grand Central Place,
New York, NY 10165, US

212 949 4319

http://www.luciddx.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment